Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
5/29/2026, 12:00:00 AM
Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.
Korean Translation
2026년 5월 29일 비소세포폐암(NSCLC) 환자의 1차 치료를 위한 칼데라십(MK-1084)에 대해 FDA로부터 혁신 치료제 지정을 승인받음.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day in New York City to provide updates on strategy and long-term financial plans is scheduled. Impact estimated at >=1% as analyst days usually provide incremental updates; the event is scheduled.
9/16/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's Q2 FY2027 earnings release is scheduled.
8/20/2026, 12:00:00 AM
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Kratos Defense & Security Solutions Inc (KTOS) · Earnings Release
Kratos is expected to announce its Q2 2026 earnings on 2026-08-06, with analysts forecasting an EPS of approximately $0.14. This event is estimated to have a ≥5% price impact and is scheduled.
8/6/2026, 12:00:00 AM